We leveraged RNA-seq data from CD138+ MM cells obtained from Moffitt patients classified as MGUS (n = 64), smoldering (SMOL; n = 57), newly diagnosed (NDMM; treatment naïve, n = 207), early relapsed/refractory (ERMM; 1–3 lines of therapy, n = 303) and late relapsed/refractory (LRMM; >3 lines of therapy n = 182) [23]. This evidence concerns the gene SDC1 and Miyoshi myopathy.